BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology® Platform At ASCO-GI Meeting

FRAMINGHAM, Mass., Jan. 24, 2020 /PRNewswire/ -- BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, today announced the presentation of initial results from a Phase 2 clinical trial at the Gastrointestinal Cancer Symposium...

from PR Newswire: https://ift.tt/2NUGODO